Table 2.

Trials evaluating somatostatin analogs

TrialPatients Studied (n)Pharmacologic TreatmentTKV (ml)GFR (ml/min)
Ruggenenti et al., 2005 (39)a
 Treatment12Octreotide LAR 40 mg every mo×6 mo2551±1053 → 2622±1111 (P<0.01)56±29 → 53±29 (P>0.05)
 ControlCross-over2461±959 → 2623±1021 (P<0.05)55±22 → 52±25 (P>0.05)
Hogan et al., 2010 (40)a
 Treatment28Octreotide LAR 40 mg every mo×12 mo1143±827 → 1128±796 (P>0.05)68±26 → 64±25 (P>0.05)
 Control14803±269 → 873±306 (P<0.05)70±28 → 66±26 (P>0.05)
 DifferenceP<0.05P=0.98
Van Keimpema et al., 2009 (41)
 Treatment27Lantreotide 120 mg every mo×24 wkMean TKV −17 (CI, −126 to 93)83 (8–158) → 80 (8–153) (P>0.05)
 Control26Mean TKV 50 (CI −99 to 199)91 (9–173) → 96 (−12 to 205) (P>0.05)b
 DifferenceP=0.02
Caroli et al., 2013 (42)a,c
 Treatment35Octreotide LAR 40 mg every mo×36 moMean ∆TKV 220±4988±4 → 76±4; annual GFR slope over 0–3 years, −3.85 (−6.2 to −1.92)
 Control35Mean ∆TKV 453±80C: 77±5 → 68±6a; annual GFR; slope over 0–3 years, −4.95 (−7.5 to −1.97)
 DifferenceP=0.25P=0.13
  • Data are presented as the mean±SD or median (interquartile range). Octreotide LAR, octreotide acetate for injectable suspension; CI, confidence interval.

  • a GFR by iothalamate clearance.

  • b Reported as creatinine μmol/L.

  • c Slope of GFR over 3 years between treatment and placebo.